In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.
about
Translational challenges of animal models in Chagas disease drug development: a reviewIdentification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection.Drug strategies targeting CYP51 in neglected tropical diseasesExperimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IVPerformance of TcI/TcVI/TcII Chagas-Flow ATE-IgG2a for universal and genotype-specific serodiagnosis of Trypanosoma cruzi infection.Acute Chagas outbreaks: molecular and biological features of Trypanosoma cruzi isolates, and clinical aspects of acute cases in Santander, Colombia.Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas diseaseNew, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.Biological factors that impinge on Chagas disease drug development.Trypanosoma cruzi I genotype among isolates from patients with chronic Chagas disease followed at the Evandro Chagas National Institute of Infectious Diseases (FIOCRUZ, Brazil).Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.
P2860
Q26796451-FE0DB182-826C-4260-92C7-36FC6ADA16F2Q28551393-B5097C16-4665-406C-AC9F-91A36A352012Q33553551-5AC891A8-6CBA-426C-9FAA-2367B1F4B3F8Q34622554-059030DE-AD53-4643-B2EB-73FFE6600DBBQ35210866-5AFB4EFE-47D9-44B5-81C9-34FDCBFA49ABQ35692509-0DD51156-5BB6-4A3F-B166-1689BA9E87F8Q36319617-C47C08C8-A424-4286-9F9B-233665785286Q36324922-5D7961A7-8C85-4507-8989-145B7A96FACDQ36668496-22C5AFA0-5398-4EA4-97DE-B31AFC99BC42Q37395315-0D315BE2-EF0D-4E46-926D-30EC6BBA8E9FQ37732551-A9A7E0B1-A0D3-47C6-A214-09A75AE38638Q39010376-BB805F82-D816-4EC4-A29B-DCA193EBE78EQ40284487-6AAF35CF-D3CB-4FC3-81B7-0CD976B2EDCBQ47115930-A55DDFE9-2A25-4CC2-9518-908E1104B9B4
P2860
In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@en
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@nl
type
label
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@en
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@nl
prefLabel
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@en
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@nl
P2093
P2860
P356
P1476
In vivo susceptibility to benz ...... the western Brazilian Amazon.
@en
P2093
Ana P M Teston
Daniele Reis
Gleison D P Bossolani
Maria G V Barbosa
Maria T Bahia
Max J O Toledo
Mônica L Gomes
Silvana M de Araújo
P2860
P356
10.1111/TMI.12014
P577
2012-11-06T00:00:00Z